Emerging drugs for the treatment of primary biliary cholangitis

被引:3
作者
Phaw, Naw April [1 ,2 ]
Dyson, Jessica Katharine [1 ,2 ]
Jones, David [1 ,2 ,3 ]
机构
[1] Newcastle Univ, Inst Translat & Clin Res, Level 4 William Leech Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[2] Newcastle Hosp NHS Fdn Trust, Hepatol Dept, Newcastle Upon Tyne, Tyne & Wear, England
[3] Newcastle Univ, NIHR Newcastle Biomed Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England
基金
英国医学研究理事会;
关键词
Primary biliary cholangitis; therapies; pruritus; fatigue; nuclear receptor; senescence; PLACEBO-CONTROLLED TRIAL; URSODEOXYCHOLIC ACID; LIVER-TRANSPLANTATION; DOUBLE-BLIND; COST-EFFECTIVENESS; INADEQUATE RESPONSE; OBETICHOLIC ACID; CIRRHOSIS; UDCA; FXR;
D O I
10.1080/14728214.2020.1751814
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Primary biliary cholangitis (PBC) is a progressive inflammatory autoimmune cholestatic liver disease. Without treatment, it may result in fibrosis and eventually end stage liver disease. In addition to the disease burden, the symptom impact on the quality of life for PBC patients is significant. Ursodeoxycholic acid, and the second-line therapy, Obeticholic acid, are the only available licensed treatments. Although there has been rapid development of novel therapies in recent years for the treatment of PBC, there are very few symptoms directed therapies. Area covered: This literature review aims to review the current treatment landscape in PBC and to explore how the next few years may unfold in the field. The current guidelines and emerging therapies in phase 2, 3 and 4 clinical trials have been included. Expert opinion: The currently available therapies are effective, but their use has limitations and challenges and there is still significant unmet need. Although there have been promising therapeutic interventions in recent years, further research into personalizing therapeutic strategies with available treatments and new agents is needed.
引用
收藏
页码:101 / 112
页数:12
相关论文
共 68 条
[1]   Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis [J].
Al-Dury, Samer ;
Wahlstrom, Annika ;
Wahlin, Staffan ;
Langedijk, Jacqueline ;
Elferink, Ronald Oude ;
Stahlman, Marcus ;
Marschall, Hanns-Ulrich .
SCIENTIFIC REPORTS, 2018, 8
[2]   Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid [J].
Angulo, P ;
Jorgensen, RA ;
Keach, JC ;
Dickson, ER ;
Smith, C ;
Lindor, KD .
HEPATOLOGY, 2000, 31 (02) :318-323
[3]  
[Anonymous], [No title captured]
[4]   Up-regulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis [J].
Banales, Jesus M. ;
Saez, Elena ;
Uriz, Miriam ;
Sarvide, Sarai ;
Urribarri, Aura D. ;
Splinter, Patrick ;
Bogert, Pamela S. Tietz ;
Bujanda, Luis ;
Prieto, Jesus ;
Medina, Juan F. ;
LaRusso, Nicholas F. .
HEPATOLOGY, 2012, 56 (02) :687-697
[5]   The Binary HCO3- Umbrella: A Unifying Hypothesis on Pathogenetic and Therapeutic Aspects of Fibrosing Cholangiopathies [J].
Beuers, Ulrich ;
Hohenester, Simon ;
Wenniger, Lucas J. Maillette de Buy ;
Kremer, Andreas E. ;
Jansen, Peter L. M. ;
Elferink, Ronald P. J. Oude .
HEPATOLOGY, 2010, 52 (04) :1489-1496
[6]   Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid [J].
Boberg, K. M. ;
Wisloff, T. ;
Kjollesdal, K. S. ;
Stovring, H. ;
Kristiansen, I. S. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 38 (07) :794-803
[7]   Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence [J].
Bosch, Alexie ;
Dumortier, Jerome ;
Maucort-Boulch, Delphine ;
Scoazec, Jean-Yves ;
Wendum, Dominique ;
Conti, Filomena ;
Morard, Isabelle ;
Rubbia-Brandt, Laura ;
Terris, Benoit ;
Radenne, Sylvie ;
Abenavoli, Ludovico ;
Poupon, Raoul ;
Chazouilleres, Olivier ;
Calmus, Yvon ;
Boillot, Olivier ;
Giostra, Emiliano ;
Corpechot, Christophe .
JOURNAL OF HEPATOLOGY, 2015, 63 (06) :1449-1458
[8]   Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score [J].
Carbone, Marco ;
Nardi, Alessandra ;
Flack, Steve ;
Carpino, Guido ;
Varvaropoulou, Nikoletta ;
Gavrila, Caius ;
Spicer, Ann ;
Badrock, Jonathan ;
Bernuzzi, Francesca ;
Cardinale, Vincenzo ;
Ainsworth, Holly F. ;
Heneghan, Michael A. ;
Thorburn, Douglas ;
Bathgate, Andrew ;
Jones, Rebecca ;
Neuberger, James M. ;
Battezzati, Pier Maria ;
Zuin, Massimo ;
Taylor-Robinson, Simon ;
Donato, Maria F. ;
Kirby, John ;
Mitchell-Thain, Robert ;
Floreani, Annarosa ;
Sampaziotis, Fotios ;
Muratori, Luigi ;
Alvaro, Domenico ;
Marzioni, Marco ;
Miele, Luca ;
Marra, Fabio ;
Giannini, Edoardo ;
Gaudio, Eugenio ;
Ronca, Vincenzo ;
Bonato, Giulia ;
Cristoferi, Laura ;
Malinverno, Federica ;
Gerussi, Alessio ;
Stocken, Deborah D. ;
Cordell, Heather J. ;
Hirschfield, Gideon M. ;
Alexander, Graeme J. ;
Sandford, Richard N. ;
Jones, David E. ;
Invernizzi, Pietro ;
Mells, George F. .
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (09) :626-634
[9]   Emerging therapies for PBC [J].
Chascsa, David Maxwell Hunter ;
Lindor, Keith Douglas .
JOURNAL OF GASTROENTEROLOGY, 2020, 55 (03) :261-272
[10]   Effects of Age and Sex of Response to Ursodeoxycholic Arid and Transplant-free Survival in Patients With Primary Biliary Cholangitis [J].
Cheung, Angela C. ;
Lammers, Willem J. ;
Perez, Carla F. Murillo ;
van Buuren, Henk R. ;
Gulamhusein, Aliya ;
Trivedi, Palak J. ;
Lazaridis, Konstantinos N. ;
Ponsioen, Cyriel Y. ;
Floreani, Annarosa ;
Hirschfield, Gideon M. ;
Corpechot, Christophe ;
Mayo, Marlyn J. ;
Invernizzi, Pietro ;
Battezzati, Pier Maria ;
Pares, Albert ;
Nevens, Frederik ;
Thorburn, Douglas ;
Mason, Andrew L. ;
Carbone, Marco ;
Kowdley, Kris V. ;
Bruns, Tony ;
Dalekos, George N. ;
Gatselis, Nikolaos K. ;
Verhelst, Xavier ;
Lindor, Keith D. ;
Lleo, Ana ;
Poupon, Raoul ;
Janssen, Harry L. A. ;
Hansen, Bettina E. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (10) :2076-+